2 Growth Stocks Ready to Profit From Cannabis 2.0

The combination of Hexo Corp (TSX:HEXO)(NYSE:HEXO) and Molson Coors Canada Inc. (TSX:TPX.B)(NYSE:TAP) looks like a winning bet.

| More on:
edit Jars of marijuana

Image source: Getty Images

In October, the cannabis game changed forever, even if many pot investors weren’t paying attention. That month, Canada legalized an entire host of new marijuana categories, the most exciting of which included new edibles and beverages.

These form factors could eventually double or triple the size of the Canadian cannabis market. Analysts are calling this emerging opportunity “Cannabis 2.0.”

The opportunity is still in its early stages, however. If you’re paying attention, you could capitalize at bargain prices. If growth tracks as expected, some stock prices could go exponential.

Only one thing matters

If you want to capitalize on new consumables categories like beverages and edibles, it helps to look at what’s worked in other markets. The biggest thing a company can do to achieve massive success in consumer markets is to create a renowned brand.

There’s a reason why Coca-Cola Co and PepsiCo, Inc. are worth a combined $500 billion. McDonald’s Corp is worth more than $150 billion, while Kraft Heinz Co is worth $40 billion. Above all else, consumers buy what they know and trust.

The same behaviour will be applied to cannabis consumables. Would you rather buy a cannabis product from a brand you already love or from a company you’ve never heard of? Trust will play a major role in purchasing decisions, especially when it comes to new cannabis users.

This stock can win

Few cannabis companies are willing to admit that they need help from existing brands. Only one company has accepted this weakness, opting instead to partner with globally recognized brands with high levels of consumer recognition. That company is Hexo Corp (TSX:HEXO)(NYSE:HEXO).

Rather than creating its own pot brands from scratch, Hexo is leveraging brands that already have decades of consumer trust and billions of dollars in ad spending.

Here’s a perfect example. In October of 2019, THC-infused beverages were made legal in Canada. Within months, Hexo was able to get its first pot-based drinks to market.

These drinks will be marketed under one of Canada’s most trusted drink brands. How was it able to achieve this?

In 2018, Hexo created a joint venture with Molson Coors Canada Inc. (TSX:TPX.B)(NYSE:TAP), which has decades of experience and brand recognition.

Over the next 12 months, the companies combined their manufacturing capabilities to design and co-create marijuana-based drinks. When legalization occurred, the joint venture was able to beat all others to market.

Ask yourself one question: Will Canadian’s be more likely to buy a Molson Coors cannabis drink, or a cannabis drink from an unknown competitor?

The answer should be clear. When it comes to competing in this rapidly emerging category, the Hexo-Molson tie-up is lightyears ahead of the competition.

Globally, alcohol sales reached $1.4 trillion in 2019. How big could cannabis drink sales get? Virtually no one is paying attention to this opportunity.

Hexo is expected to generate just $80 million in sales this year. Molson, meanwhile, is expected to earn roughly $13 billion in revenue. The cannabis opportunity could have game-changing results for both companies.

If cannabis beverage demand growth becomes even a small fraction of alcohol demand, this category could add billions in sales for both Hexo and Molson.

That’s an opportunity the market isn’t pricing in. By getting in before sales traction hits, however, you can execute on this year’s best pot trade.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »